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Fig. 3 Dynamic acquisition (60 min.) w. [11C]Methionine.
Tumor to background ratio, T/B 2.3
Fig. 4 Dynamic acquisition (180 min.) w. [18F]FDG. 
Tumor to background ratio, T/B 1.5
Conclusion
 Fully automated radiosynthesis.
 Fast and reliable production of GMP-grade [11C]MeAIB.
 pH automatically adjusted to physiologically acceptable values.
 Low residual solvent in the formulated product. 
 Significantly higher tumor to background ratio for [11C]MeAIB compared to 
[11C]Methionine and [18F]FDG in the imaging of human infiltrating 
glioblastoma.
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Fig. 2 Dynamic acquisition (60 min.) w. [11C]MeAIB. 
Tumor to background ratio, T/B 8.2
MeAIB T/B 8.2
Methionine  T/B 2.3
FDG T/B 1.5
Introduction
Amino acids and analogues thereof play an important role in the growth of many 
tumor cells. The clinical value of radiolabeled amino acids and analogues thereof 
such as methionine, fluoroethyltyrosine and fluorodopa has been confirmed in a 
plethora of studies.1 We sought to prepare, formulate and apply a metabolically 
stable analogue of the amino acid alanine for system A transport, namely [N-
methyl-11C]α-methylamino-isobutyric acid, [11C]MeAIB.2
Materials & Methods
Synthesis The labeling precursor, [11C]MeOTf, was prepared on a Tracerlab FXc
Pro by standard in-line gas-phase conversions from [11C]CO2. The [11C]MeOTf 
was bubbled through a 1:1 MeOH:MeCN solution of precursor (1 mg) and penta-
methylpiperidine (2 µL) at 5 ºC. The solution was warmed to 60 ºC for 1 min., 
where 2 M NaOH (100 µL) was added. The heating was continued for 3 min. 
Shortly after, the mixture was diluted with HPLC eluent and automatically 
injected onto a semi-preparative HPLC column via a 2 mL loop. 
The HPLC purification was performed on a Luna 5µ NH2 (250·10 mm) in 3:1 
MeCN:7.5 mM KH2PO4, pH 4.3. Hence, the fraction containing the product was 
separated and diluted with 0.2 M H3PO4 (20 mL). This solution was loaded onto a 
Strata-X-C column (1 g, 12 mL), which was washed with sterile 0.1 M HCl (15 
mL) and isotonic, sterile saline (3 mL). The product was eluted with sterile 10 mL 
2 % Na2HPO4 through a sterile filter and into a vial. 
Animal Experiments & Imaging
Male athymic nude rats (HsdHan™:RNU-Foxn1rnu) were intracranially
implanted in the right hemisphere with 300.000 low passage human glioblastoma 
single cells suspended in HBSS (Invitrogen) with 0.9% glucose (SAD 500 
mg/mL). Four weeks post-implantation, rats with infiltrating glioblastomas were 
anesthetized and PET scanned using a Siemens Inveon system after tail vein 
injection of [11C]MeAIB, [11C]Methionine or [18F]FDG. Immediately after 
injection a dynamic acquisition was commenced.
Scheme 1 Radiosynthesis of [11C]MeAIB
Fig. 1 Preparative HPLC chromatograms of [11C]MeAIB
Results
The full synthesis of [11C]MeAIB including purification by prep. HPLC, solvent 
exchange by solid phase extraction and formulation takes about 35 min. 
delivering 2–5 GBq in 10 mL sterile phosphate-buffer. In all cases pH was 
maintained between 6.3–6.8 and the content of MeCN was below 350 ppm. We 
have produced more than 40 batches in the described manner. After 
administration to orthotopically implanted nude rats, the glioblastomas were 
visualized with a tumor to background (normal brain) ratio, T/B, for [18F]FDG, 
[11C]Methionine and [11C]MeAIB of 1.5, 2.3 or 8.2, respectively. Tumors are 
indicated by arrows in figure 2–4.
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